However, studies assessing breast cancer progression that were using CB2 agonist administered within 7°days of tumor transplant have shown small tumor volumes under 100 mm3 using peritumoral (Elbaz et al., 2017) or systemic (Hanlon et al., 2016) administration. Here, CNR2 is linked to breast cancer.